No Data
Express News | Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
JMP Securities Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Raises Target Price to $74
Mirum Pharmaceuticals Price Target Raised to $74 From $69 at JMP Securities
Would Mirum Pharmaceuticals (NASDAQ:MIRM) Be Better Off With Less Debt?
Mirum Shares Surge More Than 90% in 6 Months: Here's Why
Analysts Are Bullish on These Healthcare Stocks: Annexon Biosciences (ANNX), Mirum Pharmaceuticals (MIRM)
No Data
Just Care Bears : I thought there’s a FDA approval going on on this today no news yet
Claudius NJIE Just Care Bears : yes good news is coming.
Claudius NJIE : pls run to at least 50